JP2017500017A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500017A5
JP2017500017A5 JP2016532136A JP2016532136A JP2017500017A5 JP 2017500017 A5 JP2017500017 A5 JP 2017500017A5 JP 2016532136 A JP2016532136 A JP 2016532136A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2017500017 A5 JP2017500017 A5 JP 2017500017A5
Authority
JP
Japan
Prior art keywords
culture
cells
liters
item
viable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016532136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071701 external-priority patent/WO2015095809A1/en
Publication of JP2017500017A publication Critical patent/JP2017500017A/ja
Publication of JP2017500017A5 publication Critical patent/JP2017500017A5/ja
Withdrawn legal-status Critical Current

Links

JP2016532136A 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Withdrawn JP2017500017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919629P 2013-12-20 2013-12-20
US61/919,629 2013-12-20
PCT/US2014/071701 WO2015095809A1 (en) 2013-12-20 2014-12-19 Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000268A Division JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Publications (2)

Publication Number Publication Date
JP2017500017A JP2017500017A (ja) 2017-01-05
JP2017500017A5 true JP2017500017A5 (enExample) 2018-02-08

Family

ID=52347449

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016532136A Withdrawn JP2017500017A (ja) 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Country Status (5)

Country Link
US (2) US20160289633A1 (enExample)
EP (1) EP3083933B1 (enExample)
JP (3) JP2017500017A (enExample)
DK (1) DK3083933T3 (enExample)
WO (1) WO2015095809A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TW202246486A (zh) * 2014-06-09 2022-12-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
CN108350415A (zh) * 2015-11-02 2018-07-31 阿雷斯贸易股份有限公司 调节灌注模式中重组蛋白生产概况的方法
SG11201806310TA (en) 2016-01-26 2018-08-30 Boehringer Ingelheim Int Linked perfusion to continuous-flow stirred-tank reactor cell culture system
CN115044471B (zh) 2016-08-27 2025-05-27 三维生物科技有限公司 生物反应器
WO2019055796A1 (en) * 2017-09-15 2019-03-21 Bristol-Myers Squibb Company ONLINE BIOMASS CAPACITY MONITORING DURING LARGE SCALE PRODUCTION OF POLYPEPTIDES OF INTEREST
IL273549B2 (en) 2017-10-06 2023-10-01 Lonza Ag Automated control of cell culture using Raman spectroscopy
TW202538049A (zh) 2017-10-16 2025-10-01 美商再生元醫藥公司 灌注生物反應器及相關使用方法
EP3710139A4 (en) * 2017-11-13 2021-09-08 Amgen Inc. PROTEIN PRODUCTS PRODUCTION PROCESSES
TWI827570B (zh) * 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程
CN110241012B (zh) * 2018-03-09 2022-11-01 嘉和生物药业有限公司 一种生物大分子上游分阶段截留的生产方法、生产模块及在生产中的应用
CA3098565A1 (en) * 2018-04-29 2019-11-07 Claire G. ZHANG Scalable clarification process for recombinant aav production
US12071607B2 (en) 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
EP4368699A3 (en) * 2018-07-03 2024-09-11 Bristol-Myers Squibb Company Methods of producing recombinant proteins
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
JP7453151B2 (ja) * 2018-11-02 2024-03-19 協和キリン株式会社 液体培地の調製方法
EP3914696A4 (en) * 2019-01-25 2022-12-14 Biogen MA Inc. SEED CULTIVATION METHOD FOR THE PRODUCTION OF AAV
EP3953449A1 (en) * 2019-04-11 2022-02-16 Merck Patent GmbH Cell culture media comprising keto acids
WO2021008571A1 (zh) * 2019-07-16 2021-01-21 信达生物制药(苏州)有限公司 高密度连续接种的细胞培养方法及其应用
US20220315887A1 (en) * 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
JP2023503849A (ja) 2019-11-15 2023-02-01 ロンザ リミテッド 接種物を生産するためのプロセスおよびシステム
CA3201327A1 (en) * 2020-12-08 2022-06-16 Partner Therapeutics, Inc. Manufacture of granulocyte macrophage-colony stimulating factor
BR112023017717A2 (pt) 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
EP4490278A1 (en) * 2022-03-07 2025-01-15 Ultragenyx Pharmaceutical Inc. Modified batch aav production systems and methods
JP2025529258A (ja) * 2022-09-06 2025-09-04 アムジェン インコーポレイテッド リーン灌流細胞培養法
WO2026033566A2 (en) 2024-08-09 2026-02-12 Omnibrx Biotechnologies Private Limited A multistage bioreactor system and method thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
ES2276853T3 (es) 2000-12-20 2007-07-01 Bayer Pharmaceuticals Corporation Dispositivo y procedimiento para expansion en serie de semillas de celulas de mamifero.
MXPA04001982A (es) 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
ATE503998T1 (de) 2002-02-21 2011-04-15 Tokyo Gas Co Ltd Testagentien zur beurteilung der pharmakologischen wirkung eines arzneistoffs sowie verfahren und reagentien zum screening eines arzneistoffs mit ausgezeichneter verabreichungswirkung und/oder geringer nebenwirkung aus enzyme, enzyminhibitoren oder rezeptorliganden umfassenden arzneistoffen und/oder prodrugs davon
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
CN104388324A (zh) * 2004-03-05 2015-03-04 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
BRPI0716762A2 (pt) * 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
AU2008311973B2 (en) 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
WO2009140015A2 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
RU2010146387A (ru) 2008-04-16 2012-05-27 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Модифицированные полипептиды фактора ix и их применение
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
KR20110016899A (ko) * 2008-04-23 2011-02-18 심포젠 에이/에스 폴리클로날 단백질을 제조하는 방법
KR101648765B1 (ko) * 2008-06-13 2016-08-17 센토코 오르토 바이오테크 인코포레이티드 포유류 세포 배양에서 고 생존 세포 밀도를 얻는 방법
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
CA2787942A1 (en) * 2010-01-25 2011-07-28 Ventria Bioscience Methods & compositions for improving protein production
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
SG10201913700SA (en) 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
EP2686415B1 (en) 2011-03-18 2017-11-15 GE Healthcare Bio-Sciences AB Flexible bag for cultivation of cells
CA2838695C (en) * 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality

Similar Documents

Publication Publication Date Title
JP2017500017A5 (enExample)
KR101644954B1 (ko) 배양 동안 락테이트의 축적을 감소시키는 방법 및 폴리펩타이드를 생산하는 방법
US11912739B2 (en) Sterile chromatography and manufacturing processes
KR101591671B1 (ko) 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
US11808766B2 (en) Method for generating high affinity antibodies
US9908932B2 (en) Methods of shifting an isoelectric profile of a protein product and uses thereof
CN104245922B (zh) 絮凝方法
SI2904092T1 (en) Ingredients and procedures for the production of glycoproteins
IL262923B2 (en) Direct selection of cells expressing high levels of heteromeric proteins using intergenic glutamine synthetase complementation vectors
JP2015508056A5 (enExample)
CN105378071A (zh) 用于产生稳定转染细胞的方法和组合物
JP6108170B2 (ja) 細胞培養用培地
HRP20250491T1 (hr) Upotreba monensina za regulaciju glikozilacije rekombinantnih proteina
US20160108357A1 (en) Methods of culturing a cell
JP3020300B2 (ja) 動物細胞培養用組成物、培養方法および生理活性物質の製造法
CN104854125A (zh) 在不存在全能核酸酶的情况下分离synagis*的方法
Aalilouch et al. Monoclonal antibody production using hybridoma technology: advances, challenges and applications
KR20200083564A (ko) 단백질 산물을 제조하는 방법
Pörtner et al. Cell culture technology
AU2017393059B2 (en) Method for producing corneal epithelial cell mass
RU2786078C2 (ru) Способы стерильной хроматографии и производства
Bodeus et al. In Vitro Production of Rat Monoclonal Antibodies
US11254964B1 (en) Cell culture methods for increased cell viability
Dewan Evaluation of Zinc Compounds and LongTM R3 IGF-I as Alternatives for Insulin in Serum-free Media to Support Growth and Productivity of an Sp2/0 Cell Line
CN120137879A (zh) 一种高效率正确表达具有非对称结构抗体的细胞培养方法